Coutinho et al. Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci. 2016, 17, 1065.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Advances in Therapies for Mucopolysaccharidoses.Current issues in molecular biology · 2026
   Review
2. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.Human molecular genetics · 2023
   Article
3. Molecular basis of primary hyperoxaluria: clues to innovative treatments.Urolithiasis · 2019
   Review
4. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.Nature communications · 2018
   Article

Corrections and comments

• Erratum for
  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract